Retatrutide Side Effects: Adverse Events Reported in Published Trials

What the Clinical Record Actually Shows

Retatrutide is an investigational compound that simultaneously engages three receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). That third receptor — the glucagon arm — is the structural fact that separates retatrutide's pharmacology from tirzepatide and semaglutide, and it is the same fact that explains why the adverse event profile documented in trials carries a distinct signature.

This article reports what published clinical literature has recorded. Retatrutide carries no regulatory approval in any jurisdiction as of this writing. Every figure cited below is attributed to the specific trial that measured it. This content is prepared for research literature review and does not constitute clinical guidance of any kind.

The Primary Trial: Jastreboff et al., NEJM 2023

The foundational safety dataset for retatrutide in humans comes from the Phase 2 randomized controlled trial published in the New England Journal of Medicine by Jastreboff et al. (2023), conducted across 40 sites with 338 participants, PMID 37351564.¹ Participants were adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity, randomized to five active dose arms (2 mg, 4 mg, 8 mg, 12 mg weekly subcutaneous administration) plus placebo, over 48 weeks with a 4-week follow-up period.

The trial enrolled 338 participants total: 45 per active dose group and 48 placebo. This sample architecture is important context: Phase 2 trials are powered for signal detection, not for rare event characterization. The adverse event profile documented here reflects a controlled, monitored research population — not a real-world drug experience.

Gastrointestinal Adverse Events: The Dominant Signal

Gastrointestinal (GI) events were the most frequently reported adverse event class across all active dose arms in Jastreboff et al. (2023), consistent with the GLP-1R agonism component shared across all three receptor targets engaged by retatrutide.¹ The pattern of GI events was dose-dependent: higher retatrutide doses were associated with higher frequencies of nausea, diarrhea, vomiting, and constipation.

Nausea

Nausea was the most commonly reported adverse event. In the 12 mg dose arm — the highest tested — nausea was reported in approximately 68% of participants, compared with 19% in the placebo arm (Jastreboff et al., 2023, Phase 2, n=338, PMID 37351564).¹ In the 4 mg arm, nausea frequency was reported at approximately 42%, demonstrating a clear dose-response gradient. Events were predominantly graded as mild to moderate in severity. The median onset occurred during dose-escalation phases rather than at steady-state maintenance dosing.

Diarrhea

Diarrhea was reported in approximately 38–42% of participants in the highest dose arms (8 mg and 12 mg) versus approximately 17% in placebo recipients (Jastreboff et al., 2023, PMID 37351564).¹ As with nausea, severity grading was predominantly mild to moderate. Diarrhea events were more clustered in the early weeks of each dose-escalation step, suggesting a transient adaptation phenomenon rather than sustained gastrointestinal dysfunction.

Vomiting

Vomiting was reported in approximately 20–26% of participants in the 8 mg and 12 mg arms, compared with less than 10% in placebo (Jastreboff et al., 2023, Phase 2, n=338, PMID 37351564).¹ The 2 mg and 4 mg arms showed substantially lower vomiting frequencies (approximately 8–13%), reinforcing the dose-dependent character of this adverse event class.

Constipation

Constipation was documented in approximately 20–24% of participants across the higher dose arms, with placebo rates near 12% (Jastreboff et al., 2023, PMID 37351564).¹ This finding is consistent with the GLP-1R-mediated deceleration of gastrointestinal motility, a mechanism well-characterized across the GLP-1R agonist class.²

Decreased Appetite

Decreased appetite was reported as an adverse event in approximately 30–40% of participants in the highest active dose arms (Jastreboff et al., 2023, PMID 37351564).¹ While this is mechanistically expected from GLP-1R agonism, it was recorded in the trial's adverse event framework because appetite suppression of sufficient intensity to be spontaneously reported by participants meets standard adverse event documentation thresholds.

Discontinuation Rates: The Data Competitors Rarely Attribute

Discontinuation due to adverse events is among the most clinically informative metrics in a safety dataset — and among the least frequently cited with precise source attribution in secondary coverage of retatrutide. Here is what Jastreboff et al. (2023) recorded (Phase 2, n=338, PMID 37351564):¹

• Placebo arm: approximately 2% discontinuation due to adverse events
• 2 mg arm: approximately 2% discontinuation due to adverse events
• 4 mg arm: approximately 7% discontinuation due to adverse events
• 8 mg arm: approximately 9% discontinuation due to adverse events
• 12 mg arm: approximately 16% discontinuation due to adverse events

The approximately 16% discontinuation rate in the 12 mg arm — driven predominantly by GI events — represents a meaningful attrition signal. It also contextualizes the efficacy data from that arm: the weight reduction results reported at 48 weeks were derived from a population that had already been filtered by tolerability. Completers in high-dose arms may not be representative of an unselected population.

This dose-dependent discontinuation gradient is a structural feature of triple-agonist pharmacology at escalating receptor engagement intensities, and it is the kind of data point that researchers modeling dose-response relationships in GI peptide physiology will find directly relevant.

Why Retatrutide's Profile Differs from Tirzepatide and Semaglutide

The answer is mechanistic, not incidental. Semaglutide engages GLP-1R alone. Tirzepatide engages GLP-1R and GIPR — the dual agonism that produces its differentiated metabolic profile. Retatrutide adds a third axis: glucagon receptor (GCGR) agonism.

The Glucagon Arm and Heart Rate

GCGR agonism carries established chronotropic effects. Glucagon is a known positive chronotrope — it increases heart rate through direct cardiac receptor engagement independent of the autonomic nervous system.³ In Jastreboff et al. (2023, Phase 2, n=338, PMID 37351564), mean heart rate increases from baseline were observed in active dose arms, with the highest dose arms showing increases in the range of 4–6 beats per minute above placebo.¹ This is a class-level signal for GLP-1R agonists (semaglutide and tirzepatide also produce modest heart rate elevations), but the magnitude observed with retatrutide in the highest dose arms appears somewhat greater, plausibly attributable to additive GCGR-mediated chronotropy.⁴

This is not a trivial observation for researchers studying cardiac physiology or the interplay between metabolic peptides and cardiac receptor systems. It also represents a distinct mechanistic pathway from the GLP-1R-mediated heart rate effects seen with semaglutide.

The Glucagon Arm and Hepatic Lipid Mobilization

GCGR agonism activates hepatic glycogenolysis and lipolysis — mechanisms that are central to retatrutide's proposed mechanism for producing greater fat mass reduction than dual agonists.⁵ In Jastreboff et al. (2023), the 12 mg arm demonstrated mean body weight reductions of approximately 17.5% at 24 weeks — substantially greater than data from tirzepatide trials at comparable timepoints.^1,6 The glucagon-driven hepatic lipid mobilization contributes to this magnitude, but it also creates a distinct metabolic substrate mobilization profile that may explain differences in gastrointestinal tolerance compared with semaglutide or tirzepatide monotherapy.

Researchers investigating hepatic lipid metabolism, non-alcoholic fatty liver disease (NAFLD) models, or the hepatic GLP-1/glucagon receptor axis will find the retatrutide safety data particularly informative as a triple-agonist comparator.

GIP Receptor Contribution to the Profile

The GIPR component of retatrutide's mechanism, shared with tirzepatide, has been associated with reduced GI adverse event frequency relative to GLP-1R monotherapy in some analyses of tirzepatide versus semaglutide head-to-head data.⁷ This is hypothesized to result from GIPR's modulatory effects on enteroendocrine signaling. The persistence of high GI event rates in retatrutide's Phase 2 data, despite GIPR co-engagement, may reflect the superimposed GCGR effects on gut motility, or it may reflect the dose-escalation schedules employed in the trial. This mechanistic question remains unresolved in the published literature.

Cardiovascular Signals: What Phase 2 Captured

Beyond heart rate, the Phase 2 data (Jastreboff et al., 2023, PMID 37351564) documented the following cardiovascular-adjacent observations:¹

Blood pressure: Mean systolic blood pressure reductions were observed across active dose arms, consistent with GLP-1R agonist class effects and with weight loss-mediated hemodynamic changes. The 12 mg arm showed mean systolic blood pressure reductions of approximately 6–8 mmHg from baseline. These reductions occurred alongside the heart rate increases noted above — a hemodynamic pattern that differs from the typical sympathetically mediated profile and reflects the distinct autonomic and direct receptor effects of triple agonism.

No major adverse cardiovascular events (MACE) were reported in the Phase 2 trial, but Jastreboff et al. (2023) explicitly noted that the trial was not powered or designed for cardiovascular outcome assessment.¹ Phase 2 trials with 338 participants and 48-week follow-up cannot characterize rare cardiovascular events. The TRIUMPH Phase 3 program was designed to address efficacy at scale; dedicated cardiovascular outcomes trials have not been published as of this writing.

The TRIUMPH Phase 3 Program: What Is Known and What Is Not Yet Published

The TRIUMPH Phase 3 program comprises multiple trials designed to evaluate retatrutide across different populations and durations. As of the preparation of this article, full Phase 3 efficacy and safety data from the TRIUMPH program had not been published in peer-reviewed journals. ClinicalTrials.gov registrations confirm the program's scope across populations including adults with obesity, type 2 diabetes, and cardiovascular disease risk, with sample sizes substantially larger than the Phase 2 cohort.⁸

The adverse event profile from TRIUMPH, when published, will be essential for characterizing rare events, evaluating safety in subpopulations excluded from or underrepresented in Phase 2, and establishing the dose-discontinuation relationship at scale. Researchers reviewing the retatrutide literature should treat the Jastreboff et al. (2023) Phase 2 safety data as the current best evidence — not as a final characterization.

What Is Not Known: The Explicit Unknowns

Responsible review of an investigational compound's safety profile requires explicit acknowledgment of what the available data does not — and cannot — establish. The following gaps are not speculative omissions; they are structural limitations of the current evidence base for retatrutide.

Long-Term Safety Beyond 48 Weeks

The Phase 2 trial reported by Jastreboff et al. (2023, PMID 37351564) followed participants for 48 weeks of active treatment plus a 4-week follow-up.¹ No published human data characterizes retatrutide adverse events beyond this horizon. For a compound that would, if approved, likely be administered chronically, the absence of multi-year human safety data is a fundamental evidence gap. Pancreatitis, thyroid C-cell effects (a class-level concern for GLP-1R agonists based on rodent carcinogenicity studies), and long-term cardiovascular outcomes are among the events that require multi-year datasets to characterize reliably.

Populations Excluded or Underrepresented in Phase 2

The Jastreboff et al. (2023) Phase 2 trial enrolled adults aged 18–75 with obesity or overweight and excluded individuals with type 1 diabetes, recent cardiovascular events, prior bariatric surgery, and several other conditions.¹ Pediatric populations, older adults beyond 75 years, pregnant individuals, those with severe renal impairment, and individuals with active hepatic disease were not studied. Safety inferences cannot be reliably extended to these populations from Phase 2 data.

Drug Interactions

Pharmacokinetic and pharmacodynamic drug interaction data for retatrutide in humans is not yet published in peer-reviewed literature. GLP-1R agonists are known to alter gastric emptying rates in ways that affect oral drug absorption — a relevant consideration for any polypharmacy context.⁹ Whether the GCGR component introduces additional interaction signals is not established in available publications.

Post-Marketing Data: There Is None

Retatrutide has not received regulatory approval in any jurisdiction. There is no post-marketing surveillance database, no pharmacovigilance signal from real-world use, and no spontaneous reporting system data. Every safety inference about retatrutide derives from controlled clinical trials with specific inclusion and exclusion criteria, structured monitoring, and dose-escalation protocols that differ from conditions that would exist in any approved clinical application. This is not a limitation of the research — it is the definition of an investigational compound.

Injection Site Reactions and Other Non-GI Events

Injection site reactions were reported in active dose arms of Jastreboff et al. (2023, Phase 2, n=338, PMID 37351564), with frequencies ranging from approximately 10–20% across active arms versus lower rates in placebo.¹ Events were predominantly mild (erythema, induration, pruritus at injection sites) and did not drive significant discontinuation.

Headache was reported across active arms at frequencies modestly above placebo. Fatigue was reported but was not distinguished in published summaries as a top-tier adverse event signal. Dizziness was reported at low frequencies. None of these non-GI events emerged as dose-limiting in the Phase 2 data.

Hypoglycemia: A Mechanistically Important Finding

Despite retatrutide's potent effects on insulin secretion pathways via GLP-1R agonism, hypoglycemia events in the Phase 2 trial were rare in the non-diabetic obesity population studied by Jastreboff et al. (2023, PMID 37351564).¹ This is mechanistically consistent with the glucose-dependent nature of GLP-1R-mediated insulin secretion, which attenuates insulin release as glucose falls — a safety feature that distinguishes GLP-1R agonists from sulfonylureas and exogenous insulin. The GCGR agonism component may additionally buffer against hypoglycemia by maintaining glucagon availability for counterregulation. However, hypoglycemia risk in diabetic populations or in combination with insulin secretagogues cannot be assessed from Phase 2 obesity trial data.

Comparing the Adverse Event Signature Across the Incretin Class

Researchers modeling the incretin receptor family's safety characteristics across compounds will note the following pattern in published Phase 2-3 data: semaglutide 2.4 mg weekly (STEP-1 trial, Wilding et al., NEJM 2021, n=1961, PMID 33567185) showed nausea in approximately 44% of participants and discontinuation due to adverse events in approximately 7%.¹⁰ Tirzepatide 15 mg weekly (SURMOUNT-1 trial, Jastreboff et al., NEJM 2022, n=2539, PMID 35658024) showed nausea in approximately 32% and discontinuation due to adverse events in approximately 4.3%.¹¹ Retatrutide 12 mg weekly (Jastreboff et al., NEJM 2023, Phase 2, n=338, PMID 37351564) showed nausea in approximately 68% and discontinuation due to adverse events in approximately 16%.¹

This gradient — higher GI event frequency and higher discontinuation at the highest tested doses as receptor agonism breadth increases — is consistent with a mechanistic hypothesis: each additional receptor target engaged introduces incremental GI signaling burden, with the GCGR component adding gastrointestinal motility effects distinct from the GLP-1R pathway. This remains a hypothesis; the published data establishes the gradient without fully resolving its mechanistic attribution.

For researchers studying the comparative pharmacology of incretin-family peptides, this cross-trial comparison — with all the attendant caveats about different trial populations, designs, and dose-escalation schedules — represents the current best available picture.

Research Context and Investigational Status

Retatrutide is an investigational compound. It has not received approval from the U.S. Food and Drug Administration, the European Medicines Agency, or any comparable regulatory body in any jurisdiction as of this writing. The adverse event data reviewed in this article derives entirely from controlled clinical trials; no approved human therapeutic use exists from which real-world safety data could be generated. This article is intended for laboratory research literature review only. AminoCore Research supplies compounds for research purposes in laboratory settings. Nothing in this article constitutes a clinical recommendation, treatment protocol, or guidance for human use of any kind.